---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-23-004312"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:58:51.462204+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Organicell appoints Harry Leider, MD, MBA as CEO effective June 21, 2023

## Summary
- Dr. Leider most recently served as CMO/EVP at Gelesis, gaining FDA approval for Plenity and leading the company through a NYSE IPO.
- He previously was CMO/Group VP at Walgreens Boots Alliance, leading clinical programs and health analytics across the Fortune 50.
- As CEO, he will lead Organicell, a clinical-stage biopharma developing regenerative therapies from perinatal sources for chronic diseases.
- Dr. Leider has over 25 years of healthcare executive experience, including roles at Ameritox, and academic appointments at Johns Hopkins and Harvard.

## SEC filing metadata
- accession: 0001829126-23-004312
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912623004312/0001829126-23-004312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912623004312/organicellreg_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-23-004312
- JSON: https://secwatch.observer/filing/0001829126-23-004312.json
- Plain text: https://secwatch.observer/filing/0001829126-23-004312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.